img02

INVESTORS

Overview

Escala Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech, Inc., is a development stage company focused on the clinical development and commercialization of N-acetyl-D-mannosamine (ManNAc) in collaboration with NIH investigators. Escala Therapeutics, Inc. is also seeking new academic and industry partnerships to develop other therapies for orphan/ultra-orphan, rare or neglected disorders.

Contact Information
Escala Therapeutics, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
info@escalabio.com

Escala Therapeutics Ltd
No. 1 London Bridge
London, SE1 9BG
United Kingdom
info@escalabio.com

Investor Relations
Hootan Khatami, MD, CEO
ir@escalabio.com

Escala Therapeutics